Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Moleculin Biotech, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 19 | 21 | +2 |
| Shares | 460.6K | 464.7K | +4.13K (+0.9%) |
| Value | $1.31M | $790.0K | −$518.0K (−39.6%) |
New holders (4)
Institutions that held Moleculin Biotech, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 8,939 | $15.2K | 0.00% |
| SBI Securities Co., Ltd. | 405 | $689 | 0.00% |
| Bogart Wealth, LLC | 300 | $510 | 0.00% |
| Kestra Investment Management, LLC | 25 | $43 | 0.00% |
Sold out (2)
Institutions that held Moleculin Biotech, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Danske Bank A/S | 2 | $6 |
| JPMorgan Chase & Co | 1 | $3 |